← Back to Search

Intervention Management Arm (Dapagliflozin) for Atrial Fibrillation (DAPA-AF Trial)

Phase 4
Waitlist Available
Led By Mehmet Aktas
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6-12 months
Awards & highlights

DAPA-AF Trial Summary

This trial is testing whether the diabetes medication dapagliflozin can help prevent AF following surgery to treat AF. 100 people with AF will be enrolled and randomly assigned to receive either dapagliflozin or placebo. The trial will follow participants for 12 months to see how often AF occurs.

DAPA-AF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6-12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6-12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean percentage of time spent in atrial fibrillation
Secondary outcome measures
Mean quality of life score using the QualiTy-of-life (AFEQT) Questionnaire
Percentage of participants hospitalized for heart failure post catheter ablation of AF
Rate of health care utilization

DAPA-AF Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Intervention Management Arm (Dapagliflozin)Active Control1 Intervention
A block randomization method will be use to randomize subjects to treatment with dapagliflozin 10 mg once daily. Subjects will take 1 blinded tablet of study drug (dapagliflozin) dosed once daily, per the randomization scheme, for 12 months. Each subject will be dispensed 35 blinded doses per month, during each month of participation in the trial. Quarterly pill counts will be performed to track compliance.
Group II: Control Arm (Placebo)Placebo Group1 Intervention
Subjects will take 1 blinded tablet of placebo drug dosed once daily, per the randomization scheme, for 12 months. Each subject will be dispensed 35 blinded doses per month, during each month of participation in the trial. Quarterly pill counts will be performed to track compliance.

Find a Location

Who is running the clinical trial?

University of RochesterLead Sponsor
833 Previous Clinical Trials
518,119 Total Patients Enrolled
10 Trials studying Atrial Fibrillation
5,221 Patients Enrolled for Atrial Fibrillation
AstraZenecaIndustry Sponsor
4,240 Previous Clinical Trials
288,521,615 Total Patients Enrolled
10 Trials studying Atrial Fibrillation
2,876 Patients Enrolled for Atrial Fibrillation
Mehmet AktasPrincipal InvestigatorPrincipal Investigator

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What health conditions has Intervention Management Arm (Dapagliflozin) been used to address?

"Intervention Management Arm (Dapagliflozin) is a popular pharmaceutical treatment for many medical conditions, including diet and exercise management as well as inadequate response to monotherapy."

Answered by AI

In what geographic regions is this exploration accessible?

"The current list of medical centres participating in this study include Maine Medical Center, Henry Ford Hospital, St. Luke's Hospital and Health Network, as well as 5 other facilities."

Answered by AI

Is this research opportunity currently recruiting participants?

"According to the information available on clinicaltrials.gov, this particular trial has concluded recruitment since its last update on October 7th 2022. It was initially posted on July 27 2021 and is no longer accepting applicants at present; however, there are 539 other studies that are actively seeking participants right now."

Answered by AI

Could you detail the other investigations that have been conducted surrounding Intervention Management Arm (Dapagliflozin)?

"Intervention Management Arm (Dapagliflozin) was originally researched at the University of Texas Health Science Centre in San Antonio back in 2014. As it stands, 18456 studies have been concluded while 63 are still open and recruiting participants, with numerous trials taking place in Portland Maine."

Answered by AI

What is the aggregate figure of individuals involved in this experiment?

"This trial is no longer recruiting patients, having been initially posted on July 27th 2021 and last updated October 7th 2022. However, if you are looking for other studies related to atrial fibrillation there are currently 476 trials actively enrolling participants or 63 clinical trials involving Intervention Management Arm (Dapagliflozin)."

Answered by AI

Is this the initial exploration of its kind?

"Since 2014, Intervention Management Arm (Dapagliflozin) has been a popular subject of medical research. AstraZeneca first commissioned the initial trial in that year with 700 participants and later received N/A drug approval following its publication. Nowadays there are 63 ongoing experiments for this medication across 235 cities and 50 countries."

Answered by AI

How does Dapagliflozin affect human health and wellbeing?

"Our experts at Power rated Intervention Management Arm (Dapagliflozin)'s safety as a 3 due to its Phase 4 trial status, signifying that this treatment is already authorized."

Answered by AI
Recent research and studies
~7 spots leftby Mar 2025